The FDA granted priority review for trastuzumab deruxtecan in combination with pertuzumab for first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer.
JavaScript must be enabled in order for you to use the interactive campus map. However, it seems JavaScript is either disabled or not supported by your browser. To ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback